Annamaria Mascolo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8403943/publications.pdf

Version: 2024-02-01

430874 552781 30 725 18 26 citations h-index g-index papers 31 31 31 669 docs citations times ranked citing authors all docs

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases. Drug Safety, 2016, 39, 401-407. | 3.2 | 62 |
| 2 | Can causality assessment fulfill the new European definition of adverse drug reaction? A review of methods used in spontaneous reporting. Pharmacological Research, 2017, 123, 122-129. | 7.1 | 46 |
| 3 | The Role of Renin-Angiotensin-Aldosterone System in the Heart and Lung: Focus on COVID-19. Frontiers in Pharmacology, 2021, 12, 667254. | 3.5 | 39 |
| 4 | Improvement of patient adverse drug reaction reporting through a community pharmacist-based intervention in the Campania region of Italy. Expert Opinion on Drug Safety, 2014, 13, 21-29. | 2.4 | 38 |
| 5 | Angiotensin II and angiotensin 1–7: which is their role in atrial fibrillation?. Heart Failure Reviews, 2020, 25, 367-380. | 3.9 | 37 |
| 6 | Campania Region (Italy) spontaneous reporting system and preventability assessment through a case-by-case approach: a pilot study on psychotropic drugs. Expert Opinion on Drug Safety, 2016, 15, 9-15. | 2.4 | 36 |
| 7 | Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review. Frontiers in Cardiovascular Medicine, 2020, 7, 143. | 2.4 | 35 |
| 8 | Campania Preventability Assessment Committee (Italy): A Focus on the Preventability of Non-steroidal Anti-inflammatory Drugs' Adverse Drug Reactions. Frontiers in Pharmacology, 2017, 8, 305. | 3.5 | 33 |
| 9 | The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs. Frontiers in Pharmacology, 2019, 10, 111. | 3.5 | 31 |
| 10 | Current and future therapeutic perspective in chronic heart failure. Pharmacological Research, 2022, 175, 106035. | 7.1 | 31 |
| 11 | Campania preventability assessment committee: a focus on the preventability of the contrast media adverse drug reactions. Expert Opinion on Drug Safety, 2016, 15, 51-59. | 2.4 | 30 |
| 12 | The pathophysiological role of natriuretic peptide-RAAS cross talk in heart failure. International Journal of Cardiology, 2017, 226, 121-125. | 1.7 | 28 |
| 13 | A case of figurate urticaria by etanercept. Journal of Pharmacology and Pharmacotherapeutics, 2016, 7, 106. | 0.4 | 28 |
| 14 | New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs). Expert Opinion on Drug Safety, 2016, 15, 85-100. | 2.4 | 27 |
| 15 | SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies. Pharmacological Research, 2021, 172, 105836. | 7.1 | 26 |
| 16 | PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database. Drug Safety, 2021, 44, 337-349. | 3.2 | 26 |
| 17 | Effect of Chronic Kidney Diseases on Mortality among Digoxin Users Treated for Non-Valvular Atrial Fibrillation: A Nationwide Register-Based Retrospective Cohort Study. PLoS ONE, 2016, 11, e0160337. | 2.5 | 26 |
| 18 | Suspected adverse reactions to contrast media in Campania Region (Italy): results from 14 years of post-marketing surveillance. Expert Opinion on Drug Safety, 2015, 14, 1341-1351. | 2.4 | 24 |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Quinolones-Induced Musculoskeletal, Neurological, and Psychiatric ADRs: A Pharmacovigilance Study Based on Data From the Italian Spontaneous Reporting System. Frontiers in Pharmacology, 2020, 11, 428. | 3.5 | 22 |
| 20 | Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database. Frontiers in Pharmacology, 2020, 11, 830. | 3.5 | 21 |
| 21 | Pillars and Pitfalls of the New Pharmacovigilance Legislation: Consequences for the Identification of Adverse Drug Reactions Deriving From Abuse, Misuse, Overdose, Occupational Exposure, and Medication Errors. Frontiers in Pharmacology, 2018, 9, 611. | 3.5 | 16 |
| 22 | Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System. Frontiers in Pharmacology, 2019, 10, 425. | 3.5 | 14 |
| 23 | Safety of Anticancer Agents Used in Children: A Focus on Their Off-Label Use Through Data From the Spontaneous Reporting System. Frontiers in Pharmacology, 2020, 11, 621. | 3.5 | 13 |
| 24 | Preventable statin adverse reactions and therapy discontinuation. What can we learn from the spontaneous reporting system?. Expert Opinion on Drug Safety, 2018, 17, 457-465. | 2.4 | 12 |
| 25 | Comparison of Long-Term Clinical Implications of Beta-Blockade in Patients With Obstructive Airway Diseases Exposed to Beta-Blockers With Different \hat{I}^2 1-Adrenoreceptor Selectivity: An Italian Population-Based Cohort Study. Frontiers in Pharmacology, 2018, 9, 1212. | 3.5 | 9 |
| 26 | European Safety Analysis of mRNA and Viral Vector COVID-19 Vaccines on Glucose Metabolism Events. Pharmaceuticals, 2022, 15, 677. | 3.8 | 8 |
| 27 | Contrast media-induced nephropathy: how has Italy contributed in the past 30 years? A systematic review. Therapeutics and Clinical Risk Management, 2017, Volume 13, 1463-1478. | 2.0 | 4 |
| 28 | Adverse drug reactions during hepatitis C treatment with direct-acting antivirals: The role of medication errors, their impact on treatment discontinuation and their preventability. New insights from the Campania Region (Italy) spontaneous reporting syste. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 867-876. | 1.5 | 2 |
| 29 | Response to the comment on "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies". Pharmacological Research, 2021, 172, 105863. | 7.1 | 0 |
| 30 | Response to the comment "ls SGLT2i superior to DPP4i for primary and secondary prevention of cardiovascular diseases and death in patients with type 2 diabetes?― Pharmacological Research, 2021, 174, 105876. | 7.1 | 0 |